Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.
Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.
GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.
AI life sciences models allow researchers to explore different patient populations, protocols, and development strategies before a study starts.
Editor's Picks
